Evaluation of circ_0002232 and circ-vimentin gene expressions as valuable biomarkers in acute myeloid leukemia patients
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-024-10113-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Salma Mahfouz Ibrahem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, RNA, Circular, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIM: Acute myeloid leukemia (AML) is a remarkably complex malignancy; with considerable genetic, epigenetic, and phenotypic heterogenicity. Circ-RNAs are a novel class of non-coding RNA. They may influence leukemia development and offer exciting possibilities for targeted AML diagnosis and therapy. This study aimed to detect circ_0002232 and circ-VIM expression levels in AML patients and their relation to the clinicopathological characteristics and disease outcome to assess the prognostic potential of both circ-RNAs and achieve a new target therapy for the disease. METHODS: Circ_0002232 and circ-VIM gene expressions were measured in 60 AML patients and 30 controls using qRT-PCR. RESULTS: Circ_0002232 was significantly downregulated in our patients compared to controls (P value < 0.001). On the other hand, circ-VIM was notably upregulated in our patients (P value = 0.005). Using ROC curve, circ_0002232 and circ-VIM biomarkers could distinguish AML patients from controls with AUC 0.847, 0.683 and P value < 0.0001, = 0.004 respectively. Patients with downregulated circ_0002232 were significantly younger than upregulated patients (p value = 0.003). In addition, downregulated circ_0002232 was significantly associated with decreased hemoglobin level and increased overall survival (OS). Regarding high circ-VIM expression in AML patients, it was significantly correlated with lacking complete remission and leukocytosis. CONCLUSION: Circ_0002232 and circ-VIM could be valuable diagnostic biomarkers to differentiate AML patients from healthy controls in clinical use. Circ-VIM expression may influence AML prognosis. Further research is needed to validate the clinical utility of circ_0002232 as a prognostic marker for OS in AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
- Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia. helalhetta@aun.edu.eg.
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt. helalhetta@aun.edu.eg.
Zitieren
APA
Ibrahem, S. M., Ahmed, E. H., Shafik, E. A., Hetta, H. F., & Bakry, R. M. (2025). Evaluation of circ_0002232 and circ-vimentin gene expressions as valuable biomarkers in acute myeloid leukemia patients. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10113-7
Vancouver
Ibrahem SM, Ahmed EH, Shafik EA, Hetta HF, Bakry RM. Evaluation of circ_0002232 and circ-vimentin gene expressions as valuable biomarkers in acute myeloid leukemia patients. Molecular Biology Reports. 2025. doi:10.1007/s11033-024-10113-7
BibTeX
@article{Ibrahem2025,
author = {Ibrahem, Salma Mahfouz and Ahmed, Eman Hasan and Shafik, Engy Adel and Hetta, Helal F and Bakry, Rania Mohamed},
title = {Evaluation of circ_0002232 and circ-vimentin gene expressions as valuable biomarkers in acute myeloid leukemia patients},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-024-10113-7}
}
EUVIMED